SSA
IBER

Schonfeld Strategic Advisors’s Ibere Pharmaceuticals IBER Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-135,445
Closed -$1.31M – 3072
2021
Q4 		$1.31M Hold
135,445
– – 0.01% 817
2021
Q3 		$1.31M Buy
+135,445
New +$1.31M 0.01% 855

Other funds holding IBER

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return

Schonfeld Strategic Advisors's IBER Position: Q1 2022 in Review

Schonfeld Strategic Advisors sold out of Ibere Pharmaceuticals (IBER) in Q1 2022, closing a stake of 135,445 shares — an estimated $1.31M sold.

Schonfeld Strategic Advisors first reported a position in IBER in Q3 2021 and held it in 2 quarters. The position peaked at $1.31M in Q4 2021. 48 funds tracked by Wall St. Rank hold IBER as of Q1 2022.

  • Schonfeld Strategic Advisors reported no remaining Ibere Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 135,445 Ibere Pharmaceuticals shares in Q1 2022, an estimated $1.31M.
  • Schonfeld Strategic Advisors first reported a position in Ibere Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Ibere Pharmaceuticals position peaked at $1.31M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2022, filed 16 May 2022.